Pharmacy Benefits Management in the Veterans Health Administration: 1995 to 2003

American Journal of Managed Care

Volumn 11, Issue 2, 2005, Pages 104-112

  Sales, Mariscelle M ^a,e   Cunningham, Francesca E ^a,b   Glassman, Peter A ^c   Valentino, Michael A ^a   Good, Chester B ^d  

^a HG   (Netherlands)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF PITTSBURGH   (United States)

^e DEPARTMENT OF VETERANS AFFAIRS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIHISTAMINIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GENERIC DRUG; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; STATINE DERIVATIVE;

ADULT; AGED; COST CONTROL; DRUG EFFICACY; DRUG FORMULARY; DRUG SAFETY; EVIDENCE BASED MEDICINE; FEMALE; HEALTH CARE MANAGEMENT; HEALTH CARE POLICY; HEALTH CARE SYSTEM; HEALTH PROMOTION; HUMAN; MALE; OUTCOMES RESEARCH; PHARMACY BENEFIT MANAGER; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; SOLDIER;

CLINICAL PHARMACY INFORMATION SYSTEMS; CONTRACT SERVICES; DISEASE MANAGEMENT; DRUG COSTS; DRUG UTILIZATION REVIEW; DRUGS, GENERIC; FORMULARIES, HOSPITAL; HOSPITAL INFORMATION SYSTEMS; HOSPITALS, VETERANS; HUMANS; INSURANCE BENEFITS; INSURANCE COVERAGE; INSURANCE, PHARMACEUTICAL SERVICES; MEDICATION ERRORS; OUTCOME ASSESSMENT (HEALTH CARE); UNITED STATES; UNITED STATES DEPARTMENT OF VETERANS AFFAIRS;

EID: 13844289131     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (49)

1. Emigh RC, ed. Novartis Pharmacy Benefit Report: Facts and Figures. 2002 ed. East Hanover, NJ: Novartis; 2002.
2. Public Law 104-262: 104th Congress. Veterans, Health Care Eligibility Reform Act of 1996. October 9, 1996. Available at: http://frwebgate.access.gpo. gov/cgi-bin/useftp.cgi?IPaddress=wais.access.gpo.gov&filenames=publ262. pdf&directory=/disk3/wais/data/104_cong_public_laws. Accessed January 21, 2005.
3. Schulman KA, Rubenstein LE, Abernethy DR, et al. The effect of pharmaceutical benefits managers: is it being evaluated? Ann Intern Med. 1996;124:906-913.
4. Blumenthal D, Herdman R, eds; VA Pharmacy Formulary Analysis Committee, Division of Hearth Care Services, Institute of Medicine. Description and Analysis of the VA National Formulary. Washington, DC: National Academy Press; January 2000.
5. US General Accounting Office. VA Drug Formulary: Better Oversight Is Required, but Veterans Are Getting Needed Drugs (GAO-01-183). Report to the Ranking Member, Committee on Veterans' Affairs, US Senate. January 2001. Available at: http://www.gao.gov/new.items/d01183.pdf. Accessed September 23, 2002.
6. US General Accounting Office. VA Health Care: VA's Management of Drugs on Its National Formulary (GAO/HEHS-00-34). Report to the Ranking Minority Member, Committee on Veterans' Affairs, US Senate. December 1999. Available at http://www.gao.gov/archive/2000/he00034.pdf. Accessed September 23, 2002.
7. Pharmacy Benefits Management Strategic Healthcare Group, Department of Veterans Affairs. Home page. Available at: http://www.vapbm.org/PBM/menu.asp.
8. Glassman PA, Good CB, Kelley ME, et al. Physician perceptions of a national formulary. Am J Manag Care. 2001;7:241-251.
9. Glassman PA, Good CB, Kelley ME, Bradley M, Valentino M. Physician satisfaction with formulary policies: is it access to formulary or nonformulary drugs that matters most? Am J Manag Care. 2004;10:209-216.
10. Burk M, Furmaga E, Dong D, Cunningham F. Multicenter drug use evaluation of tamsulosin and availability of guidance criteria for nonformulary use in the Veterans Affairs health system. J Manag Care Pharm. September-October 2004;10:423-432.
11. Burk M, Morreale AP, Cunningham F. Conversion from troglitazone to rosiglitazone or pioglitazone in the VA: a multicenter DUE. Formulary. 2004;39:310-317.
12. Siegel D, Lopez J, Meier J, Cunningham FE. Changes in the pharmacologic treatment of hypertension in the Department of Veterans Affairs 1997-1999: decreased use of calcium antagonists and increased use of beta-blockers and thiazide diuretics. Am J Hypertens. 2001;4(9 pt 1):957-962.
13. Ren XS, Kazis LE, Lee AF, et al. Patient characteristics and prescription patterns of atypical antipsychotics among patients with schizophrenia. J Clin Pharm Ther. 2002;27:441-451.
14. Siva C, Eisen S, Shepherd R, et al. Leflunomide use during the first 33 months after FDA approval: experience with a national cohort of 3325 patients. Arthritis Care Res. 2003;49:745-751.
15. Hammed A, Lee A, Ren S, Miller DM, Cunningham FE, Kazis L. Use of antidepressant medications: are there differences in psychiatric visits among patient treatments in the Veterans Administration? Med Care. 2004;42:551-559.
16. Charbonneau A, Berlowitz D, Kasiz L, Miller DM, Cunningham FE, Ren X. Monitoring depression care: in search of an accurate quality indicator. Med Care. 2004;42:522-531.
17. London MJ, Itani KMF, Perrino AC, et al. Perioperative beta blockade: a survey of physician attitudes in the Department of Veterans Affairs. J Cardiothorac Vasc Anesth. 2004;18:14-24.
18. Huang J, Casebeer A, Plomondon M, et al. Prescription-filling rates for key medications in Veterans Affairs patients after coronary artery bypass grafting. Am J Health Syst Pharm. 2004;61:1248-1252.
19. Lopez, J, Meier, J, Siegal D, Cunningham F. Antihypertensive medication use in the Department of Veterans Affairs: a national analysis of prescribing patterns from 2000-2002. Am J Hypertens. 2004 Dec;17(12 part 1):1095-1099.
20. Furmaga EM, Glassman PA, Cunningham FE, Good CB. Using a national pharmaceutical database to reduce prescribing of short-acting nifedipine in patients with hypertension. Advances in Patient Safety: From Research to Implementation. 2004. Rockville, Md: Agency for Healthcare Research and Quality.
21. Ereshefsky L, Riesenman C, Lam YW. Antidepressant drug interactions and the cytochrome P450 system: the role of cytochrome P450 2D6. Clin Pharmacokinet. 1995;29(suppl 1):10-18; discussion 18, 19.
22. Otton SV, Wu D, Joffe RT, et al. Inhibition by fluoxetine of cytochrome P450 2D6 activity. Clin Pharmacol Ther. 1993;53:401-409.
23. Hemeryck A, Belpaire FM. Selective serotonin reuptake inhibitors and cytochrome P450 mediated drug-drug interactions: an update. Curr Drug Metab. 2002;3:13-37.
24. Hare CB, Vu MP, Grunfeld C, et al. Simvastatin-nelfinavir interaction implicated in rhabdomyolysis and death. Clin Infect Dis. 2002;35:e111-112.
25. Fichtenbaum CJ, Gerber JG. Interactions between antiretroviral drugs and drugs used for the therapy of the metabolic complications encountered during HIV infection. Clin Pharmacokinet. 2002;41:1195-1211.
26. Williams D, Feely J. Pharmacokinetic-pharmacodynamic drug interactions with HMC-CoA reductase inhibitors. Clin Pharmacokinet. 2002;41:343-370.
27. Cheng CH, Miller C, Lowe C, et al. Rhabdomyolysis due to probable interaction between simvastatin and ritonavir. Am J Health Syst Pharm. 2002;59:728-730.
28. Piliero PJ. Interaction between ritonavir and statins. Am J Med. 2002;112:510-511.
29. Fichtenbaum CJ, Gerber JG, Rosenkranz SL, et al. Pharmacokinetic interactions between protease inhibitors and statins in HIV-seronegative volunteers: ACTG Study A5047. AIDS. 2002:16:569-577.
30. Hsyu PH, Schultz-Smith MD, Lillibridge JH, et al. Pharmacokinetic interactions between nelfinavir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and simvastatin. Antimicrob Agents Chemother. 2001;45:3445-3450.
31. ICAAC: nelfinavir interacts with statins and an antiseizure drug. AIDS Read. 2000;10:644.
32. Ballantyne CM, Corsini A, Davidson MH, et al. Risk for myopathy with statin therapy in high-risk patients. Arch Intern Med. 2003;163:553-564.
33. Elisaf M. Effects of fibrates on serum metabolic parameters. Curr Med Res Opin. 2002;18:269-276.
34. Hamilton-Craig I. Statin-associated myopathy. Med J Aust. 2001;175:486-489.
35. Tomlinson B, Chan P, Lan W. How well tolerated are lipid-lowering drugs? Drugs Aging. 2001;18:665-683.
36. Omar MA, Wilson IP, Cox TS. Rhabdomyolysis and HMC-CoA reductase inhibitors. Ann Pharmacother. 2001;35:1096-1107.
37. Shek A, Ferrill MJ. Statin-fibrate combination therapy. Ann Pharmacother. 2001;35:908-917.
38. Biswas AK, Zabrocki LA, Mayes KL, et al. Cardiotoxicity associated with intentional ziprasidone and bupropion overdose. J Toxicol Clin Toxicol. 2003;41:79-82.
39. Kelly DL, Love RC. Ziprasidone and the QTc interval: pharmacokinetic and pharmacodynamics considerations. Psychopharmacol Bull. 2001;35:66-79.
40. Guthrie SK. Clinical issues associated with maintenance treatment of patients with schizophrenia. Am J Health Syst Pharm. 2002;59(17 suppl 5):S19-24.
41. Bellnier TJ. Continuum of care: stabilizing the acutely agitated patient. Am J Health Syst Pharm. 2002:59(17 suppl 5):S12-18.
42. Gunasekara NS, Spencer CM, Keating GM. Spotlight on ziprasidone in schizophrenia and schizoaffective disorder. CNS Drugs. 2002;16:645-652.
43. Haddad PM, Anderson IM. Antipsychotic-related QTc prolongation, torsade de pointes and sudden death. Drugs. 2002;62:1649-1671.
44. Taylor DM. Prolongation of QTc interval and antipsychotics. Am J Psychiatry. 2002;159:1062; author reply 1064.
45. Gunasekara NS, Spencer CM, Keating GM. Ziprasidone: a review of its use in schizophrenia and schizoaffective disorder. Drugs. 2002;62:1217-1251.
46. Caley CF, Cooper CK. Ziprasidone: the fifth atypical antipsychotic. Ann Pharmacother. 2002;36:839-851.
47. Stimmel GL, Gutierrez MA, Lee V. Ziprasidone: an atypical antipsychotic drug for the treatment of schizophrenia. Clin Ther. 2002;24:21-37.
48. Goodnick PJ. Ziprasidone: profile on safety. Expert Opin Pharmacother. 2001;2:1655-1662.
49. Glassman AH, Bigger TJ Jr. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry. 2001;158:1774-1782.